InveniAI Announces Successful Completion of Milestone in its Collaboration with PRISM BioLab Focused on Designing Novel Inflammasome-Targeted Therapeutic Candidates
July 20, 2021 08:10 ET
|
InveniAI LLC
- Successful generation of INVA8003, a peptidomimetic inhibitor of PYCARD (often referred to as ASC, apoptosis-associated speck-like protein containing CARD) triggers milestone payment to PRISM BioLab...
Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
July 19, 2021 08:00 ET
|
Prometheus Biosciences
-First precision approach to IBD by utilizing a companion diagnostic to identify patients- -Phase 2a initiation in Crohn’s Disease on track for 3rd Quarter 2021- - Further details to be provided at...
Global Stoma/Ostomy Care Market Research Report 2021: Rising Incidence of Colorectal Cancer, Bladder Cancer, and IBD and Drives the Need for Ostomy Care Products
July 16, 2021 04:08 ET
|
Research and Markets
Dublin, July 16, 2021 (GLOBE NEWSWIRE) -- The "Stoma/Ostomy Care - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Stoma/Ostomy Care...
Ulcerative Colitis Clinical Landscape Report 2021: Pipeline Holds Multiple Novel Prospects in Terms of Distinct Mechanisms of Action and Biologics
July 12, 2021 05:33 ET
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering. UC typically presents with bloody diarrhea, which may...
Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
June 17, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory...
Progenity Announces $40 Million Private Placement
June 10, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive securities...
Progenity Launches Strategic Transformation into Biotech Company, Eliminating Costs of Progenity Genetics Lab and Focusing on Robust, Innovative R&D Pipeline
June 02, 2021 07:00 ET
|
Progenity, Inc.
Closure of genetics lab and other operational improvements expected to result in approximately 70% reduction of annual capital required for operations – from more than $180 million currently to...
Progenity Provides Results from Key Study for Its Targeted Therapeutics Program
May 26, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced results from a further study for the company’s Targeted Therapeutics...
Progenity Announces Poster Presentations at Digestive Disease Week 2021
May 24, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, May 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the presentation of two posters related to the company’s Targeted...
Progenity Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 13, 2021 16:03 ET
|
Progenity, Inc.
Reports revenues of $24.5 million in the first quarter of 2021, up 72% from prior quarter Announced pre-validation data for its Preecludia™ test showed strong performance consistent with...